Nanobiotix Stock Hits New Record at €45.86
Nanobiotix stock continues its climb this Thursday, May 14. The French biotech's share reached a new all-time high of €45.86 during the session, surpassing the previous peak of €45.72. The stock is trading at €45.34 in mid-afternoon, up 2.81% from the previous day's close.
A Historic High of €45.86 Extends a 118% Rally Over Three Months
The Nanobiotix stock registered a new absolute high of €45.86 during the session before slightly receding to €45.34. The previous peak, at €45.72, was just the day before. The performance now shows nearly 31% for the week and 118% over three months. Over one year, the stock has recorded a gain of 1,247%. The movement is part of a series of records set since early May. The stock had already marked successive highs at €41.52 on May 11, then €44.44 on May 12. The momentum began in early May following the FDA's validation of an amendment to the Phase 3 NANORAY-312 trial protocol on head and neck cancer, sponsored by Johnson & Johnson. The biotech ranks 13th in the SBF 120 this Thursday, in a broad index that is up 0.82% during the session.
The Stock Enters a Marked Overbought Zone, at 113% of the Bollinger Band
The price is at 113% of the Bollinger Band (upper limit at €42.36), indicating an exceedance of the upper boundary and a signal of overbought. The stock is significantly above all its moving averages: the MM20 at €31.29 is nearly 45% distant, the MM200 at €19.07 is more than 137% distant. The technical resistance threshold of €43.78 was breached with today's high. The previous support point can be identified at the MM20 level, more than €14 below the current price. The one-month volatility stands at 24.59, a high level reflecting the magnitude of the recent movement. No financial publications are scheduled in the immediate future. The next clinical data related to the NANORAY-312 trial, whose schedule was altered by the amendment validated in early May, remains the reference point for the future trajectory.
